Validation of EUROArray HPV test using the VALGENT framework.

Area of Science:

• Molecular Diagnostics
• Gynecologic Oncology
• Public Health Screening

Background:

• Clinical validation of human papillomavirus (HPV) tests is crucial for cervical cancer screening.
• Most high-risk HPV infections are transient, necessitating accurate and reliable testing methods.

Purpose of the Study:

• To evaluate the EUROArray HPV test using the VALGENT framework for analytical and clinical performance.
• Determine if the EUROArray HPV test meets international performance metrics for cervical cancer screening.

Main Methods:

• The EUROArray HPV test was evaluated on 1300 consecutive and 300 abnormal cervical samples from Slovenia.
• Clinical performance for detecting cervical intraepithelial neoplasia grade 2 and above (CIN2+) was compared to Hybrid Capture 2 (HC2).
• Intra- and inter-laboratory reproducibility was assessed on 500 samples.

Main Results:

• At the predefined cutoff, EUROArray HPV showed lower sensitivity than HC2 for CIN2+ detection (relative sensitivity 0.93).
• An optimized cutoff improved performance, achieving relative sensitivity of 0.98 and relative specificity of 1.00 for CIN2+.
• The assay demonstrated excellent intra- and inter-laboratory reproducibility (concordance ≥ 94%, Kappas ≥0.85).

Conclusions:

• EUROArray HPV, at a predefined cutoff, was less sensitive than HC2 for CIN2+ detection.
• With an optimized cutoff, the EUROArray HPV test met international criteria for use in cervical cancer screening.